Company: JUNS
Filing Date: 2025-11-26
Form Type: S-1
Source: 0001493152-25-025204
Chunk: 156

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-26
Form: S-1
Chunk 156
---
ase.
Children who have parents with MPS-I will carry the defective gene.

MPS-I patients are presently
treated with an Enzyme Replacement Therapy (“ERT”) named Aldurazyme. This requires a weekly infusion of 4 hours per event
and costs over $500,000 per year per patient. The ERT is effective in significantly prolonging life. However, since the ERT does not penetrate
the blood brain barrier, ears, eyes, or joints, it leaves the patients with a gradually worsening quality of life including loss of hearing,
blindness and severe arthritis.

JNS102 is targeting the specific areas that ERT
cannot treat, with JOTROL™ treatment.

JNS102 Phase II Clinical Trial

| 1. | Preclinical studies conducted at University of Miami in MPS-I mice results showed that a high dose of resveratrol increased the alpha-L-iduronidase which is the critical enzyme that is too low in these patients. |
| 2. | IND application for Phase I study was approved by the FDA and the clinical                                                                                                                                          
 trial is completed. Results documented in the section JOTROL™ Phase I PK and Safety Study.                                                                                                                          |
| 3. | Final study details and start to be determined by consultation with the FDA and supportive additional financing.                                                                                                    |

| 89 |

| 4. | Primary endpoint: |

| ● | Safety, tolerability and PK/PD values |

| 5. | Secondary endpoints to include (subject to FDA acceptance) |

| i.   | Improvement in 6-minute walk distance          |
| ii.  | Forced vital capacity                          |
| iii. | Biomarkers, such as alpha-L-iduronidase levels |
| iv.  | MPS-I validated pain survey                    |

JNS107 Phase II trial for MELAS Syndrome

JNS107 is utilizing JOTROL™
as the product to treat MELAS Syndrome.

MELAS (Mitochondrial Encephalopathy,
Lactic Acidosis, and Stroke-like episodes) syndrome is a rare disorder that begins in childhood, usually between two and fifteen years
of age, and mostly affects the nervous system and muscles. The most common early symptoms are seizures, recurrent headaches, loss of
appetite, and recurrent vomiting. Stroke-like episodes with temporary muscle weakness on one side of the body (hemiparesis) may also
occur and this can lead to altered consciousness, vision and hearing loss, loss of motor skills, and